ArticleJournal of autism and developmental disorders2021

Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).

Véronique Crutel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.